Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2025)

Tango Therapeutics has reported Capital Expenditures over the past 6 years, most recently at $826000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $826000.0 for Q4 2025, up 566.13% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (up 38.99% YoY), and the annual figure for FY2025 was $1.0 million, up 38.99%.
  • Capital Expenditures for Q4 2025 was $826000.0 at Tango Therapeutics, up from -$34000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TNGX hit a ceiling of $6.7 million in Q4 2022 and a floor of -$2.4 million in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $159500.0 (2024), compared with a mean of $484300.0.
  • Peak annual rise in Capital Expenditures hit 2662.74% in 2022, while the deepest fall reached 4940.0% in 2022.
  • Tango Therapeutics' Capital Expenditures stood at -$263000.0 in 2021, then surged by 2662.74% to $6.7 million in 2022, then plummeted by 118.72% to -$1.3 million in 2023, then skyrocketed by 109.83% to $124000.0 in 2024, then surged by 566.13% to $826000.0 in 2025.
  • The last three reported values for Capital Expenditures were $826000.0 (Q4 2025), -$34000.0 (Q3 2025), and $205000.0 (Q2 2025) per Business Quant data.